

HUMAN CD14 ELISA

Catalog Number: C1431-K01 For Research Use Only. Not for use in diagnostic procedures. v. 3 (16 OCT 24)

> EAGLE BIOSCIENCES, INC. 20A Northwest Blvd., Suite 112, Nashua, NH 03063 Phone: 617-419-2019 Fax: 617-419-1110 WWW.EAGLEBIO.COM



INTENDED USE

The Eagle Biosciences Human CD14 ELISA kit is a solid phase sandwich ELISA for the in-vitro qualitative and quantitative determination of CD14 in supernatants, buffered solutions or serum and plasma samples. This assay will recognize both natural and recombinant human CD14.

For further information about this kit, its application, or the procedures in this insert, please contact the Technical Service Team at Eagle Biosciences, Inc at <u>www.EagleBio.com</u> or at 866-411-8023.

INTRODUCTION

CD14 is described as the marker molecule for monocytes and macrophages and as an important component of the innate immune system. It exists in two forms : mCD14 a 55 kDa protein anchored to the membrane by a glycosylphosphoinositol tail (GPI) and two soluble serum proteins (sCD14) with or without the GPT anchor. The mCD14 is critical for lipopolysaccharide (LPS) dependent signal transduction, and sCD14 confers LPS sensitivity to cells lacking mCD14. CD14 is strongly expressed on cells of the myelomonocytic lineage such as monocytes and osteoclast progenitors and at a lower level on macrophages, Langerhans cells, granulocytes and microglia.

Increased sCD14 levels are associated with inflammatory infectious diseases or allergy.

CD14 is involved in clearance of gram-negative bacteria via its high affinity binding to LPS-LPB complexes. CD14 is a useful marker for enumeration of monocytes or osteoclast progenitors in peripheral blood and for monocytic and myelomonocytic acute myeloid leukaemia.

PRINCIPLE OF THE ASSAY

A capture Antibody highly specific for CD14 has been coated to the wells of the microtiter strip plate provided during manufacture. Binding of CD14 in samples and known standards to the capture antibodies is completed and then any excess unbound analyte is removed.

During the next incubation period the binding of the Biotinylated anti-CD14 secondary antibody to the analyte occurs. Any excess unbound secondary antibody is then removed.

The HRP conjugate solution is then added to every well including the zero wells, following incubation excess conjugate is removed by careful washing.

A chromogen substrate is added to the wells resulting in the progressive development of a blue coloured complex with the conjugate. The colour development is then stopped by the addition of acid turning the resultant final product yellow. The intensity of the produced coloured complex is directly proportional to the concentration of CD14 present in the samples and standards.

The absorbance of the colour complex is then measured and the generated OD values for each standard are plotted against expected concentration forming a standard curve. This standard curve can then be used to accurately determine the concentration of CD14 in any sample tested.

Reagents (Store@2-8°C)	Quantity 1x96 well kit	Reconstitution		
96 well microtiter strip plate	1	Ready to use (Pre-coated)		
Plastic plate covers	2	n/a		
Standard: 220 ng/ml	2 vials	Reconstitute as directed on the vial (see Assay preparation, section 8)		
Standard Diluent (Buffer)	1 vial (15ml)	10x Concentrate, dilute in distilled water (see reagent preparation, section 8)		
Biotinylated anti-CD14	1 vial (0.4ml)	Dilute in Biotinylated Antibody Diluent (see Assay preparation, section 8)		

REAGENTS PROVIDED



Biotinylated Antibody Diluent	1 vial (7ml)	Ready to use
Streptavidin-HRP	2 vials (5µl)	Add 0.5ml of HRP diluent prior to use (see Assay preparation, section 8)
HRP Diluent	1 vial (12ml)	Ready to use
Wash Buffer	1 vial (10ml)	200x Concentrate dilute in distilled water (see Assay preparation, section 8)
TMB Substrate	1 vial (11ml)	Ready to use
H ₂ SO ₄ stop reagent	1 vial (11ml)	Ready to use

MATERIALS REQUIRED BUT NOT PRIVDED

- 1. Microtiter plate reader fitted with appropriate filters (450nm required with optional 630nm reference filter)
- 2. Microplate washer or wash bottle
- 3. 10, 50, 100, 200 and 1,000µl adjustable single channel micropipettes with disposable tips
- 4. 50-300µl multi-channel micropipette with disposable tips
- 5. Multichannel micropipette reagent reservoirs
- 6. Distilled water
- 7. Vortex mixer
- 8. Miscellaneous laboratory plastic and/or glass, if possible sterile

STORAGE AND STABILITY

Store kit reagents between 2 and 8°C. Immediately after use remaining reagents should be returned to cold storage (2-8°C). Expiry of the kit and reagents is stated on box front labels. The expiry of the kit components can only be guaranteed if the components are stored properly, and if, in case of repeated use of one component, the reagent is not contaminated by the first handling.

Wash Buffer 1X: Once prepared, store at 2-8° C for up to 1 week.

Standard Diluent Buffer 1X: Once prepared, store at 2-8°C for up to 1 week. **Reconstituted Standard:** Once prepared use immediately and do not store. **Diluted Blotinylated Anti-CD14:** Once prepared use immediately and do not store. **Diluted Streptavidin-HRP:** Once prepared use immediately and do not store.

SPECIMEN COLLECTION AND STORAGE

Cell culture supernatants, human serum, plasma or other biological samples will be suitable for use in the assay. Remove serum from the clot or red cells, respectively, as soon as possible after clotting and separation.

Cell culture supernatants: Remove particulates and aggregates by spinning at approximately 1000 x g for 10 min.

Serum: Use pyrogen/endotoxin free collecting tubes. Serum should be removed rapidly and carefully from the red cells after clotting. Following clotting, centrifuge at approximately 1000 x g for 10 min and remove serum.

Plasma: EDTA, citrate and heparin plasma can be assayed. Spin samples at 1000 x g for 30 min to remove particulates. Harvest plasma.

Storage: If not analysed shortly after collection, samples should be aliquoted (250-500µl) to avoid repeated freeze-thaw cycles and stored frozen at -70°C. Avoid multiple freeze-thaw cycles of frozen specimens.



Recommendation: Do not thaw by heating at 37°C or 56° C. Thaw at room temperature and make sure that sample is completely thawed and homogeneous before use. When possible avoid use of badly hemolyzed or lipemic sera. If large amounts of particles are present these should be removed prior to use by centrifugation or filtration.

SAFETY AND PRECAUTIONS

- Handling of reagents, serum or plasma specimens should be in accordance with local safety procedures, e.g. CDC/NIH Health manual: "Biosafety in Microbiological and Biomedical Laboratories" 1984.
- Laboratory gloves should be worn at all times.
- Avoid any skin contact with H2SO4 and TMB. In case of contact, wash thoroughly with water.
- Do not eat, drink, smoke or apply cosmetics where kit reagents are used.
- Do not pipette by mouth.
- When not in use, kit components should be stored refrigerated as indicated on vials or bottles labels.
- All reagents should be warmed to room temperature before use. Lyophilized standards should be discarded after use.
- Once the desired number of strips has been removed, immediately reseal the bag to protect the remaining strips from deterioration.
- Cover or cap all reagents when not in use.
- Do not mix or interchange reagents between different lots.
- Do not use reagents beyond the expiration date of the kit.
- Use a clean disposable plastic pipette tip for each reagent, standard, or specimen addition in order to avoid cross contamination, for the dispensing of H2SO4 and TMB Substrate solutions, avoid pipettes with metal parts.
- Use a clean plastic container to prepare the washing solution.
- Thoroughly mix the reagents and samples before use by agitation or swirling.
- All residual washing liquid must be drained from the wells by efficient aspiration or by decantation followed by tapping the plate forcefully on absorbent paper. Never insert absorbent paper directly into the wells.
- The TMB Substrate solution is light sensitive. Avoid prolonged exposure to light. Also, avoid contact of the TMB Substrate solution with metal to prevent colour development. Warning TMB Substrate is toxic avoid direct contact with hands. Dispose off properly.
- If a dark blue colour develops within a few minutes after preparation, this indicates that the TMB Substrate solution has been contaminated and must be discarded. Read absorbances within 1 hour after completion of the assay.
- When pipetting reagents, maintain a consistent order of addition from well-to-well. This will ensure equal incubation times for all wells.
- Follow incubation times described in the assay procedure.
- Dispense the TMB Substrate within 15 min of the washing of the microtiter plate.

ASSAY PREPARATION

Bring all reagents to room temperature before use



ASSAY DESIGN

Determine the number of microwell strips required to test the desired number of samples plus appropriate number of wells needed for running zeros and standards. Each sample, standard, zero should be tested in duplicate. Remove sufficient microwell strips for testing from the pouch immediately prior to use. Return any wells not required for this assay with desiccant to the pouch. Seal tightly and return to 2-8°C storage.

	Standards		Samp	Sample Wells								
	1	2	3	4	5	6	7	8	9	10	11	12
А	220	220										
В	110	110										
С	55	55										
D	27.5	27.5										
E	13.75	13.75										
F	6.875	6.875										
G	zero	zero										
Н												

PREPARATION OF WASH BUFFER

If crystals have formed in the concentrate Wash Buffer, warm it gently until complete dissolution. Dilute the (200X) concentrate Wash Buffer 200 fold with distilled water to give a 1X working solution. Pour entire contents (10 ml) of the concentrate Wash Buffer into a clean 2,000 ml graduated cylinder. Bring final volume to 2,000 ml with glass-distilled or deionized water. Mix gently to avoid foaming. Transfer to a clean wash bottle and store at 2-25°C

PREPARATION OF STANDARD DILUENT BUFFER

If crystals have formed in the concentrate Standard Diluent, warm it gently until complete dissolution. Dilute the (10X) concentrate Standard Diluent 10 fold with distilled water to give a 1X working solution. Pour entire contents of the concentrate Standard Diluent into a clean appropriate graduated cylinder. Bring to final volume with glass-distilled or deionized water. Transfer to a clean wash bottle and store at 2-25°C. Please see example volumes below:

Standard Diluent Concentrate (ml)	Distilled water (ml)
15	135
25	225

PREPARATION OF STANDARD

Standard vials must be reconstituted with the volume of Standard Diluent Buffer 1X shown on the vial immediately prior to use. This reconstitution gives a stock solution of 220 ng/ml of CD14. Mix the reconstituted standard gently by inversion only. Serial dilutions of the standard are made directly in the assay plate to provide the concentration range from 220 to 6.875 ng/ml. A fresh standard curve should be produced for each new assay.



- Immediately after reconstitution add 200µl of the reconstituted standard to wells A1 and A2, which provides the highest concentration standard at 220 ng/ml.
- Add 100µl of Standard Diluent Buffer 1X to the remaining standard wells B1 and B2 to F1 and F2.
- Transfer 100µl from wells A1 and A2 to B1 and B2. Mix the well contents by repeated aspirations and ejections taking care not to scratch the inner surface of the wells.
- Continue this 1 :1 dilution using 100µl from wells B1 and B2 through to wells F1 and F2 providing a serial diluted standard curve ranging from 220 ng/ml to 6.875 ng/ml.
- Discard 100µl from the final wells of the standard curve (F1 and F2).

Alternatively these dilutions can be performed in separate clean tubes and immediately transferred into the relevant wells.

PREPARATION OF SAMPLES

Before testing, human serum or plasma samples have to be diluted 1:50 in Standard Diluent Buffer 1X.

PREPARATION OF BIOTINYLATED ANTI-CD14

It is recommended this reagent is prepared immediately before use. Dilute the Biotinylated Anti-CD14 with the Biotinylated Antibody Diluent in an appropriate clean glass vial using volumes appropriate to the number of required wells. Please see example volumes below:

Number of wells required	Biotinylated Antibody (µl)	Biotinylated Diluent (µl)
16	40	1060
24	60	1590
32	80	2120
48	120	3180
96	240	6360

PREPARATION OF STREPTAVIDIN-HRP

It is recommended to centrifuge vial for a few seconds in a microcentrifuge to collect all the volume at the bottom.

Dilute the 5 µl vial with 0.5ml of Streptavidin-HRP Diluent immediately before use. Do not keep this diluted vial for future experiments. Further dilute the HRP solution to volumes appropriate for the number of required wells in a clean glass vial. Please see example volumes below:

Number of wells required	Streptavidin-HRP (µl)	Streptavidin-HRP Diluent (µl)
16	30	2
24	45	3
32	60	4
48	75	5
96	150	10



ASSAY PROCEDURE

We strongly recommend that every vial Is mixed thoroughly without foaming prior to use. Prepare all reagents as shown In section 8.

Note: final preparation of Biotinylated Antibody (section 8.6) and Streptavidin-HRP (section 8.7) should occur immediately before use.

Assay Step		Details				
1.	Addition	Prepare Standard curve as shown in section 8.4				
2.	Addition	Add 100µl of each standard, sample and zero (Standard Diluent) in duplicate to appropriate number of wells				
3.	Incubation	Cover with a plastic plate cover and incubate at room temperature (18 to 25°C) for 2 hours				
4.	Wash	 Remove the cover and wash the plate as follows: a) Aspirate the liquid from each well b) Dispense 0.3 ml of 1x washing solution into each well c) Aspirate the contents of each well d) Repeat step b and c another two times 				
5.	Addition	Add 50µl of diluted biotinylated anti-CD14 to all wells				
6.	Incubation	Cover with a plastic plate cover and incubate at room temperature (18 to 25°C) for 1 hour				
7.	Wash	Repeat wash step 4.				
8.	Addition	Add 100µl of Streptavidin-HRP solution into all wells				
9.	Incubation	Cover with a plastic plate cover and incubate at room temperature (18 to 25°C) for 30 min				
10.	Wash	Repeat wash step 4.				
11.	Addition	Add 100 μ l of ready-to-use TMB Substrate Solution into all wells				
12.	Incubation	Incubate in the dark for 10-15 minutes * at room temperature. Avoid direct exposure to light by wrapping the plate in aluminium foil				
13.	Addition	Add 100µl of H₂SO₄:Stop Reagent into all wells				
Rea	Read the absorbance value of each well (immediately after step 13.) on a spectrophotometer					

Read the absorbance value of each well (immediately after step 13.) on a spectrophotometer using 450 nm as the primary wavelength and optionally 630 nm as the reference wave length (610 nm to 650 nm is acceptable).

*Incubation time of the substrate solution is usually determined by the ELISA reader performance. Many ELISA readers only record absorbance up to 2.0 O.D. Therefore the colour development within individual microwells must be observed by the analyst, and the substrate reaction stopped before positive wells are no longer within recordable range



DATA ANALYSIS


Calculate the average absorbance values for each set of duplicate standards and samples. Ideally duplicates should be within 20% of the mean.

Generate a linear standard curve by plotting the average absorbance of each standard on the vertical axis versus the corresponding CD14 standard concentration on the horizontal axis.

The amount of CD14 in each sample is determined by extrapolating OD values against CD14 standard concentrations using the standard curve.

Standard	CD14 Conc (ng/ml)	OD (450nm) Mean	CV (%)
1	220	1.924	1.4
2	110	1.035	0.3
3	55	0.484	0.1
4	27.5	0.178	0.0
5	13.75	0.081	1.7
6	6.87	0.038	1.4
Zero	0	0.028	-

Example CD14 Standard curve



Note: curve shown above should not be used to determine results. Every laboratory must produce a standard curve for each set of microwell strips assayed.

For samples human serum or plasmas which have been diluted 1:50 according to the protocol, the calculated concentration should be multiplied by the dilution factor (x50).

ASSAY LIMITATIONS

Do not extrapolate the standard curve beyond the maximum standard curve point. The dose-response is non-linear in this region and good accuracy is difficult to obtain. Concentrated samples above the maximum standard concentration must be diluted with Standard Diluent Buffer or with your own sample buffer to produce an OD value within the range of the standard curve. Following analysis of such samples always multiply results by the appropriate dilution factor to produce actual final concentration.

The influence of various drugs on end results has not been investigated. Bacterial or fungal contamination and laboratory cross-contamination may also cause irregular results. Improper or insufficient washing at any stage of the procedure will result in either false positive or false negative results. Completely empty wells before dispensing fresh Wash Buffer, fill with Wash Buffer as indicated for each wash cycle and do not allow wells to sit uncovered or dry for extended periods. Disposable pipette tips, flasks or glassware are preferred, reusable glassware must be washed and thoroughly rinsed of all detergents before use.

As with most biological assays conditions may vary from assay to assay therefore a fresh standard curve must be prepared and run for every assay.



PERFORMANCE CHARACTERISTICS

Sensitivity

The sensitivity or minimum detectable dose of CD14 using this Eagle Biosciences Human CD14 ELISA kit was found to be 6ng/ml. This was determined by adding 2 standard deviations to the mean OD obtained when the zero standard was assayed in 6 independent experiments.

Precision

Sample	n	Mean (ng/mL)	SD	CV%	Sample	n	Mean (ng/mL)	SD	CV%
А	8	210.5	2.6	1.23 %	А	8	210.5	1.55	0.73
В	8	23.4	1.14	4.9 %	В	8	24	2	8.3

Expected Serum Values

Sample Matrix	Number of samples evaluated	Range (µg/ml)	Mean (µg/ml)
Serum	73	2.2-18.3	7.4

REFERENCES

- 1. Simmons DL and al, Blood. 1989 Jan;73(1):284-9.
- 2. Kitchens RL, Chem Immunol. 2000;74:61-82.
- 3. Tapping RI and al, Chem Immunol. 2000;74:108-21
- 4. Ranoa DR and al, J Biol Chem. 2013Apr5;288(14):9729-41
- 5. De Pablo-Bernal, R. S. et al., J Gerontol A Biol Sci Med Sci.,2015: glv121
- 6. De Pablo-Bernal, R. S. et al., The Journal of Infectious Disease, 2016; 213(6): 999-1007
- 7. G6mez-Mora, E. et al., PLoS One. 2017 Sep 21;12(9):e0184433.
- 8. Kasang, C. et al., PLoS One,2016 ;11(1):e0146678
- 9. Kasang, C. et al., BMC Infect Dis., 2012; 12: 14
- 10. Kurowski, M. et al., Arch Med Sci. 2018 Jan; 14(1):60-68.
- 11. Loo, W. T. et al., J Transl Med., 2012;10 Suppl 1: S9
- 12. Magnusson, M. K. et al., J Crohns Colitis, 2015;9(1): 56-65
- 13. Massanella, M. et al., PLoS One, 2014; 9(12): e114142
- Mendez-Lagares, G. et al., J. Antimicrob. Chemother., 2012; 10.1093/ jac/dkr594
 Pica!, M. Q. et al., PLoS One, 2017; 12(1): e0169164.
- 16. Puertas, M.C. et al., J Antimicrob Chemother. 2018 Jul 1;73(7):1940-1948
- 17. Rotger, M. et al., J Clin Invest., 2011; 121(6): 2391-400
- 18. van Lelyveld, S. F. et al., PLoS One, 2015; 10(7): e0132430
- 19. Vitalle, J. et al., Front Immunol. 2018 Jul 23;9:1709
- 20. Wittkop, L. et al., The Journal of Infectious Disease, 2013; 207:622-627



WARRANTY INFORMATION

Eagle Biosciences, Inc. warrants its Product(s) to operate or perform substantially in conformance with its specifications, as set forth in the accompanying package insert. This warranty is expressly limited to the refund of the price of any defective Product or the replacement of any defective Product with new Product. This warranty applies only when the Buyer gives written notice to the Eagle Biosciences within the expiration period of the Product(s) by the Buyer. In addition, Eagle Biosciences has no obligation to replace Product(s) as result of a) Buyer negligence, fault, or misuse, b) improper use, c) improper storage and handling, d) intentional damage, or e) event of force majeure, acts of God, or accident.

Eagle Biosciences makes no warranties, either expressed or implied, except as provided herein, including without limitation thereof, warranties as to marketability, merchantability, fitness for a particular purpose or use, or non-infringement of any intellectual property rights. In no event shall the company be liable for any indirect, incidental, or consequential damages of any nature, or losses or expenses resulting from any defective product or the use of any product. Product(s) may not be resold, modified, or altered for resale without prior written approval from Eagle Biosciences, Inc.

For further information about this kit, its application or the procedures in this kit, please contact the Technical Service Team at Eagle Biosciences, Inc. at info@eaglebio.com or at 866-411-8023.